Sign in

    Daniel Bronder

    Research Analyst at Cantor Fitzgerald

    Daniel Bronder is an Equity Research Associate at Cantor Fitzgerald, specializing in biotechnology sector research and supporting coverage of companies such as Ascendis Pharma A/S. He brings postdoctoral research experience from Memorial Sloan Kettering Cancer Center before transitioning into equity research at Cantor Fitzgerald. Bronder started at Cantor Fitzgerald after his academic fellowship, primarily assisting in biotechnology company analysis as part of a senior analyst's team. His professional credentials align with typical industry standards for associate analysts, though specific FINRA registrations or notable rankings are not publicly documented.

    Daniel Bronder's questions to Ascendis Pharma (ASND) leadership

    Daniel Bronder's questions to Ascendis Pharma (ASND) leadership • Q2 2025

    Question

    Daniel Bronder of Cantor Fitzgerald, on for Lee Watsak, asked about patient compliance and pull-through for Yorvipath and sought clarification that the reported 1,500 patient figure represented net new patient starts.

    Answer

    President & CEO Jan Møller Mikkelsen cited long-term data from Europe showing an extremely low true discontinuation rate of only a few percent, which he attributed to the significant therapeutic benefit. He also confirmed that the enrollment figures refer to unique new patient prescriptions.

    Ask Fintool Equity Research AI

    Daniel Bronder's questions to CURIS (CRIS) leadership

    Daniel Bronder's questions to CURIS (CRIS) leadership • Q3 2024

    Question

    Speaking on behalf of Li Watsek, Daniel Bronder from Cantor Fitzgerald asked about the contribution of ibrutinib in the PCNSL trial and whether the FDA might question it. He also asked how Curis intends to prioritize its PCNSL program versus its AML and MDS programs.

    Answer

    President and CEO James Dentzer explained that the trial's design, which enrolls patients immediately after they progress on a BTK inhibitor, implicitly addresses the contribution of ibrutinib. He also cited historical data showing Curis's salvage line data is outperforming second-line BTK inhibitor data. Regarding prioritization, he called it a 'high-class headache' and confirmed that PCNSL is the top priority currently due to the ongoing FDA discussions and high unmet need.

    Ask Fintool Equity Research AI